ScoreWhy is Gan & Lee Pharmaceuticals Co., Ltd. ?
1
Poor long term growth as Net Sales has grown by an annual rate of 3.44% and Operating profit at -12.66% over the last 5 years
2
The company has declared Positive results for the last 8 consecutive quarters
- NET SALES(HY) At CNY 2,062.17 MM has Grown at 23%
- ROCE(HY) Highest at 8.23%
- RAW MATERIAL COST(Y) Fallen by -1.71% (YoY)
3
With ROE of 7.85%, it has a expensive valuation with a 4.25 Price to Book Value
- Over the past year, while the stock has generated a return of 37.52%, its profits have risen by 117.6% ; the PEG ratio of the company is 0.5
- At the current price, the company has a high dividend yield of 1.8
4
Market Beating Performance
- The stock has generated a return of 37.52% in the last 1 year, much higher than market (China Shanghai Composite) returns of 22.49%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Gan & Lee Pharmaceuticals Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Gan & Lee Pharmaceuticals Co., Ltd. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Gan & Lee Pharmaceuticals Co., Ltd.
35.92%
0.87
37.43%
China Shanghai Composite
16.01%
1.58
14.20%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
3.44%
EBIT Growth (5y)
-12.66%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.21
Sales to Capital Employed (avg)
0.27
Tax Ratio
5.32%
Dividend Payout Ratio
144.23%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
12.46%
ROE (avg)
7.70%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
54
Industry P/E
Price to Book Value
4.25
EV to EBIT
64.14
EV to EBITDA
45.84
EV to Capital Employed
5.00
EV to Sales
11.86
PEG Ratio
0.46
Dividend Yield
1.82%
ROCE (Latest)
7.79%
ROE (Latest)
7.85%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend14What is working for the Company
NET SALES(HY)
At CNY 2,062.17 MM has Grown at 23%
ROCE(HY)
Highest at 8.23%
RAW MATERIAL COST(Y)
Fallen by -1.71% (YoY
NET PROFIT(9M)
Higher at CNY 755.31 MM
-1What is not working for the Company
CASH AND EQV(HY)
Lowest at CNY 5,403.5 MM
Here's what is working for Gan & Lee Pharmaceuticals Co., Ltd.
Net Profit
At CNY 755.31 MM has Grown at 109.32%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (CNY MM)
Net Sales
At CNY 2,062.17 MM has Grown at 23%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (CNY MM)
Net Profit
Higher at CNY 755.31 MM
than preceding 12 month period ended Sep 2025MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months
Net Profit (CNY MM)
Raw Material Cost
Fallen by -1.71% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Gan & Lee Pharmaceuticals Co., Ltd.
Cash and Eqv
Lowest at CNY 5,403.5 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
